Postprandial hyperglycemia is one of the earliest abnormalities of glucose homeostasis associated with type-2 diabetes and it is markedly exaggerated in diabetic patients with fasting hyperglycemia. An extensive body of data demonstrates a strong association between postprandial glucose levels and cardiovascular risk factors. Our article will focus on the concept of postprandial hyperglycemia, its physiopathology, its role on cardiovascular risk factors and the effects of new devices and a new faster insulin analog on postprandial hyperglycemia.

Background: Artificial intelligence (AI) is poised to fundamentally reshape healthcare delivery, offering unprecedented advancements in diagnostics, treatment personalization, and operational efficiency. However, a growing body of international research reveals a critical “optimism–knowledge gap”: healthcare professionals are enthusiastic about AI’s potential but possess limited technical knowledge and practical experience. This gap compromises the safe and effective implementation of AI tools. The Italian healthcare context presents a unique and amplifying challenge, as it is defined by the stringent “human-in-the-loop” oversight mandated by the Garante per la protezione dei dati personali (Italy’s Data Protection Authority). This legal framework makes clinician competence not just a goal, but a prerequisite for regulatory compliance. Objective: This study aimed to provide an exploratory quantitative assessment of AI awareness, practical application, and understanding of its limitations among a sample of clinicians in Italy. It specifically sought to compare the preparedness of hospital-based clinicians and general practitioners (GPs) and to identify the workforce’s perceived educational needs within this unique legal environment. Methods: A descriptive, cross-sectional survey was conducted from February to August 2025. Using a non-probability convenience sampling method via professional networks, the survey yielded 362 total responses. Data were analyzed descriptively and inferentially using Chi-square (${\chi }^2$) tests to compare cohort responses on familiarity, practical exposure, knowledge of limitations, and interest in further training. Results: A universal and high demand for education was found, with 89.9% of all respondents being “Moderately” or “Very” interested in learning more about AI. This optimism coexists with dangerously low practical exposure. The gap was most profound among GPs, 44.1% of whom have “Never” used an AI tool—a rate significantly higher than hospital clinicians (34.9%; ${\chi }^2=3.14$, p = 0.045). Furthermore, 32.6% of GPs admitted that they “understand some benefits but not the limitations.” Conclusions: Italian clinicians mirror the global optimism–knowledge gap. These findings underscore the urgent need for structured, continuous education in AI literacy to address ethical and regulatory imperatives within the Italian healthcare system.

The introduction of direct oral anticoagulants (DOACs), particularly factor Xa (FXa) inhibitors, has transformed the prevention and treatment of thromboembolic events. These agents have largely replaced vitamin K antagonists across most indications due to their predictable pharmacokinetics, reduced rates of intracranial bleeding, and overall ease of use. Nevertheless, a substantial residual bleeding risk remains, particularly gastrointestinal bleeding and clinically relevant non-major bleeding in elderly, frail, or polymedicated patients. Furthermore, the management of patients with severe renal dysfunction, active cancer, especially gastrointestinal or genitourinary malignancies and those requiring complex pharmacological regimens, continues to pose significant challenges. These limitations have intensified interest in targeting earlier steps of the coagulation cascade, specifically factor XI (FXI) and its activated form (FXIa). FXI occupies a unique mechanistic position: it contributes substantially to pathological thrombosis while playing only a limited role in physiological hemostasis. Genetic, observational, and mechanistic evidence consistently demonstrates that FXI deficiency confers protection against venous thromboembolism and cardiovascular events while causing minimal spontaneous bleeding. This biological paradigm has catalyzed the development of novel FXI/FXIa inhibitors, including small-molecule agents (asundexian, milvexian) and biological therapies (abelacimab). Clinical trials such as AXIOMATIC-TKR, PACIFIC-AF, and OCEANIC-AF, and ongoing programmes including ASTER and MAGNOLIA suggest that FXI inhibition may preserve antithrombotic efficacy while substantially reducing bleeding risk. This review summarizes the current landscape of oral FXa inhibitors, outlines the biological rationale for FXI/FXIa inhibition, and discusses the evolving clinical evidence supporting what may represent the next major advance in anticoagulant therapy.

Background: In 1983 Plaitakis and Duvoisin identified Homeric moly with Galanthus nivalis L., and read the Circe episode as the earliest recorded use of an anticholinesterase against antimuscarinic poisoning. The identification held for four decades. Recent multidisciplinary criticism has now put its philological and biogeographical foundations in doubt. Objective: To ask what survives of the pharmacological thesis once those foundations are removed — by reconstructing the clinical phenotype the poem describes, extracting the constraints the texts actually impose, and testing five candidate taxa against them. Methods: Critical review, integrating the Homeric and classical sources (Theophrastus, Dioscorides) with Amaryllidaceae phytochemistry and with the clinical toxicology of antimuscarinic delirium. Results: The phenotype as narrated, delirium with inner awareness preserved (noos empedos), corresponds closely to central antimuscarinic toxicity. Five constraints emerge from the texts: a dark-tunicated bulb, a white flower, arduous extraction, an inland habitat, and the pharmacodynamic capacity to reverse the syndrome. Against these, Galanthus nivalis performs well on morphology and pharmacology and badly on biogeography, being effectively absent from the Aegean lowlands. Peganum harmala does possess anticholinesterase activity, contrary to a claim often made in this debate, but its habit is wrong and so is its ecology. Allium nigrum belongs to the moly of the later botanists and offers no centrally acting mechanism; Mandragora belongs to the kykeon, not to the cure. Only Pancratium spp. satisfy all five, and they do so for a reason no other candidate can supply: contractile roots that bury the bulb, accounting for precisely the difficulty of extraction that Theophrastus singled out as diagnostic. Conclusions: The pharmacological reading of the episode stands. The single-species identification does not, and should give way to a clade-level hypothesis centred on the Mediterranean Amaryllidoideae, with Pancratium as the likeliest archetype — that is, to an ancient ethnobotanical complex in which empirical antidotal knowledge was carried by a group of plants rather than by one.